Javascript must be enabled to continue!
Differential responses of receptor tyrosine kinases C‐Met and EGFR in mice
View through CrossRef
In previous studies, we have demonstrated the critical roles of EGFR and HGFR (c‐Met) for liver regeneration and for conversion of hepatocytes to cholangiocytes by a “clean” partial hepatectomy model, in which hepatocytes and cholangiocytes grow rapidly and synchronously. In contrast, the vast majority of liver diseases involve a prolonged pathologic duration, therefore multiple types of cells participate and play different roles in the variant stages. However, it is not fully understood how EGFR and Met play their roles in this complicated setting. In this study, we explore the role of MET and EGFR signaling pathways in biliary injury after common bile duct ligation. Mice with inhibition of EGFR signaling alone (EGFRi) showed abolished hepatocyte proliferation and biliary duct cell proliferation (Ki67 immunochemistry staining) at 2, 5, and 7 days after BDL. However, Met knockout mice (KO) showed increased proliferation of cholangiocytes at 2, 5, and 7 days. Met KO mice subjected to BDL surgery had an increase of the CK19‐ marked ductular reaction at 2, 5, and 7 days. In contrast, EGFRi mice showed a reduced ductular reaction at the same time point. There was enhanced immunohistochemistry for Sox9 in EGFRi mice, but absence of its expression in Met KO mice at 7 days post‐BDL. From western blot results of total liver tissue lysate, we found increased EpCAM expression after BDL at 7 days in Met KO but not in EGFRi mice. In addition, we also observed that both p‐Merlin and cleaved p‐Mst1, components of the Hippo pathway, decreased only in Met knockout mice. Mice with combined disruption of Met and EGFR signaling became very ill by 24 hours and died at 1 to 2 days after bile duct ligation. From Kaplan‐Meier analysis, both EGFR inhibition and Met knockout mice had decreased survival rates starting at 11 days, though the survival rate of Met KO mice was overall much better than EGFRi mice by around 40%. We also observed that p‐Ezrin (Thr567) was downregulated in either Met KO or EGFRi mice, while the total Ezrin expression did not change.ConclusionsOur study demonstrates that both c‐Met and EGFR control biliary response to bile duct ligation. The cholangiocyte responses, however, were very different between these two receptors. Their combined disruption led to acute liver failure and early death following bile duct ligation. The receptor tyrosine kinases c‐Met and EGFR may play different roles in the biliary injury‐repair responses, including proliferation, trans‐differentiation, and bi‐potential progenitor cells activation.
Title: Differential responses of receptor tyrosine kinases C‐Met and EGFR in mice
Description:
In previous studies, we have demonstrated the critical roles of EGFR and HGFR (c‐Met) for liver regeneration and for conversion of hepatocytes to cholangiocytes by a “clean” partial hepatectomy model, in which hepatocytes and cholangiocytes grow rapidly and synchronously.
In contrast, the vast majority of liver diseases involve a prolonged pathologic duration, therefore multiple types of cells participate and play different roles in the variant stages.
However, it is not fully understood how EGFR and Met play their roles in this complicated setting.
In this study, we explore the role of MET and EGFR signaling pathways in biliary injury after common bile duct ligation.
Mice with inhibition of EGFR signaling alone (EGFRi) showed abolished hepatocyte proliferation and biliary duct cell proliferation (Ki67 immunochemistry staining) at 2, 5, and 7 days after BDL.
However, Met knockout mice (KO) showed increased proliferation of cholangiocytes at 2, 5, and 7 days.
Met KO mice subjected to BDL surgery had an increase of the CK19‐ marked ductular reaction at 2, 5, and 7 days.
In contrast, EGFRi mice showed a reduced ductular reaction at the same time point.
There was enhanced immunohistochemistry for Sox9 in EGFRi mice, but absence of its expression in Met KO mice at 7 days post‐BDL.
From western blot results of total liver tissue lysate, we found increased EpCAM expression after BDL at 7 days in Met KO but not in EGFRi mice.
In addition, we also observed that both p‐Merlin and cleaved p‐Mst1, components of the Hippo pathway, decreased only in Met knockout mice.
Mice with combined disruption of Met and EGFR signaling became very ill by 24 hours and died at 1 to 2 days after bile duct ligation.
From Kaplan‐Meier analysis, both EGFR inhibition and Met knockout mice had decreased survival rates starting at 11 days, though the survival rate of Met KO mice was overall much better than EGFRi mice by around 40%.
We also observed that p‐Ezrin (Thr567) was downregulated in either Met KO or EGFRi mice, while the total Ezrin expression did not change.
ConclusionsOur study demonstrates that both c‐Met and EGFR control biliary response to bile duct ligation.
The cholangiocyte responses, however, were very different between these two receptors.
Their combined disruption led to acute liver failure and early death following bile duct ligation.
The receptor tyrosine kinases c‐Met and EGFR may play different roles in the biliary injury‐repair responses, including proliferation, trans‐differentiation, and bi‐potential progenitor cells activation.
Related Results
Abstract 5463: Development of a novel antibody-maytansinoid conjugate, IMGN289, for the treatment of EGFR-expressing solid tumors.
Abstract 5463: Development of a novel antibody-maytansinoid conjugate, IMGN289, for the treatment of EGFR-expressing solid tumors.
Abstract
EGFR is an attractive target for the treatment of a variety of solid tumors because of its role as a driver oncogene and high level of expression. Four EGFR...
EGFR-to-Src family tyrosine kinase switching in proliferating-DTP TNBC cells creates a hyperphosphorylation-dependent vulnerability to EGFR TKI
EGFR-to-Src family tyrosine kinase switching in proliferating-DTP TNBC cells creates a hyperphosphorylation-dependent vulnerability to EGFR TKI
ABSTRACT
Triple-Negative Breast Cancer (TNBC) is the most aggressive type of breast malignancy, with chemotherapy as the only mainstay treatment. TNBC patients have...
Plasma ctDNA biomarker study in patients with non-small cell lung cancer with EGFR exon 20 insertion mutation treated with sunvozertinib.
Plasma ctDNA biomarker study in patients with non-small cell lung cancer with EGFR exon 20 insertion mutation treated with sunvozertinib.
8563 Background: There are limited reports on biomarker studies of non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutation (exon...
Abstract B120: Preclinical assessment of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.
Abstract B120: Preclinical assessment of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.
Abstract
Non-small cell lung cancer (NSCLC) patients with activating epidermal growth factor receptor (EGFR) mutations initially respond well to first generation rev...
EGFR Tyrosine Kinase Inhibitors Prolong Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients with Postsurgical Recurrence
EGFR Tyrosine Kinase Inhibitors Prolong Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients with Postsurgical Recurrence
It is indisputable that epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) prolong progression-free survival in non-small-cell lung cancer (NSCLC) patients ...
Abstract 2205: Identification of potential biomarker related to EGFR mutation by functional proteome profiling in primary non-small cell lung cancer
Abstract 2205: Identification of potential biomarker related to EGFR mutation by functional proteome profiling in primary non-small cell lung cancer
Abstract
Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of lung cancers which the leading cause of cancer-related death worldwide. Recently, epide...
Data from The Renin–Angiotensin System Mediates EGF Receptor–Vitamin D Receptor Cross-Talk in Colitis-Associated Colon Cancer
Data from The Renin–Angiotensin System Mediates EGF Receptor–Vitamin D Receptor Cross-Talk in Colitis-Associated Colon Cancer
<div>Abstract<p><b>Purpose:</b> We previously showed that EGF receptor (EGFR) promotes tumorigenesis in the azoxymethane/dextran sulfate sodium (AOM/DSS) mo...
Abstract 1819: Acquired T790M mutation after first generation EGFR tyrosine kinase retreatment
Abstract 1819: Acquired T790M mutation after first generation EGFR tyrosine kinase retreatment
Abstract
Introduction The first or second generation EGFR TKI drugs showed good overall response and progression free survival rates in EGFR mutation positive patien...

